Inflammatory Myositis Treatment market Size, Share, Industry, Forecast and outlook (2024-2031)

Market Overview

Global inflammatory myositis treatment market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.

Inflammatory myositis is a disease that makes the immune system attack the muscles. It is mainly characterized by chronic inflammation and swelling that comes and goes over a long time. Eventually, this inflammation makes muscles feel increasingly weak. It can also cause muscle pain. Inflammatory myositis is a type of myopathy. An injury, infection, or autoimmune disease can cause it. The two specific kinds are polymyositis and dermatomyositis. 

Polymyositis causes muscle weakness, usually in the muscles closest to the trunk of the body. Dermatomyositis causes muscle weakness, plus a skin rash. Moreover, the diseases have no cure, but corticosteroids, immunosuppressants, intravenous immunoglobulins, and other treatments are used for the successful management of the symptoms. The first choice of treatment for myositis is corticosteroids, which are usually given in high doses. Steroids can be given as tablets or injections. They should reduce the inflammation quickly, and settle muscle pain and the feeling of being unwell.

Market Scope

Market Dynamics:

Drivers

Increasing demand for novel therapeutics 

There is an increasing demand for novel therapeutics, which is expected to drive the global market over the forecast period. The novel therapeutics aim to address the unmet needs associated with the management of inflammatory myositis by providing alternative or complementary treatment options for better disease management. 

For instance, on May 16, 2023, Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, cleared the Company’s second Investigational New Drug (IND) application for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, and it has been cleared by the U.S. Food and Drug Administration (FDA) in patients with active idiopathic inflammatory myopathy including inflammatory myositis.

Moreover, many clinical trials are going on for the development of novel therapeutics that show better results in inflammatory myositis treatment. For instance, on April 04, 2023, Abcuro commenced a registrational Phase ll/lll trial of ABC008 for the treatment of inclusion body myositis. ABC008 is an anti-KLRG1 antibody that has been designed to selectively reduce highly cytotoxic T cells without harming regulatory and central memory T cells.

In addition, the regulatory approvals increase the trust in patients about the development of novel therapeutics. For instance, on July 20, 2021, The U.S. Food and Drug Administration (FDA) granted approval to Octapharma USA for Octagam 10% [Immune Globulin Intravenous], the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis, a rare immune-mediated inflammatory disease.

Further, the increasing prevalence of inflammatory myositis, rising FDA approvals, increasing clinical trials, increasing awareness and advancements in the development of novel drugs and therapies are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with the high doses of corticosteroids and other drugs,  the high cost of the treatment of inflammatory myositis and lack of better treatment for the treatment are expected to hamper the market. 

Segment Analysis

The global inflammatory myositis treatment market is segmented based on disease type, treatment type, distribution channel and region.

The corticosteroids segment accounted for approximately 39.2% of the inflammatory myositis treatment market share

The corticosteroids segment is expected to hold the largest market share over the forecast period. Usually, there is no cure for this disease, but corticosteroids are considered first-line therapeutics for the management of inflammatory myositis. Corticosteroids such as prednisone, hydrocortisone, prednisolone, methylprednisolone and other glucocorticoids are the most commonly used for inflammatory myositis.

Due to the rising prevalence especially polymyositis and dermatomyositis, the demand for the use of corticosteroids is continuously increasing. For instance, according to the National Institute of Health, 2023, the estimated prevalence of polymyositis and dermatomyositis is 5 to 22 per 100,000 persons, and the incidence is approximately 1.2 to 19 per million persons at risk per year. The incidence of myositis is increasing over time due to an increase in the detection rate.

Moreover, according to the NIH, corticosteroids are the initial therapy and cornerstone in managing both polymyositis and dermatomyositis. The common practice is to start with prednisone 1 to 2 mg/kg/day. In patients with severe weakness and those with extramuscular involvement, intravenous methylprednisolone 1mg/day for three consecutive days may be used. Patients should be closely followed, and a steroid dose can be slowly tapered based on the clinical response. 

Further, their wide availability, acceptability, and, ease of application helps to hold the largest market share. The corticosteroids can also used by combining with other drugs, these combining drugs are considered especially in cases where a single drug modality may not be sufficient. In addition, their wide adoption also increases the demand for the corticosteroids. 

Geographical Analysis

North America accounted for approximately 40.2% of the market share 

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing research activities. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies and medical device companies. The presence of major players actively performing in clinical trials, which leads to the launch of novel therapeutics and alternative treatment options.

For instance, on May 03, 2022, Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, cleared the topline results from the PRESIDIO Phase 2 clinical trial of zetomipzomib (KZR-616) in patients with dermatomyositis (DM) and polymyositis (PM). 

In addition, on June 24, 2021, Corbus Pharmaceuticals Holdings, Inc., an immunology company developing innovative medicines that target inflammation, fibrosis, metabolism and immuno-oncology, released the topline positive results from the Phase 3 DETERMINE study of lenabasum in adults with the rare, heterogeneous, autoimmune disease dermatomyositis. 

Furthermore, increasing research activities also helps to develop more advanced therapeutics for the better management of the symptoms in the early stages. As the research activities increase, the therapeutics are developed more precisely by reducing the adverse effects and complications associated with the therapeutics, which results in better patient outcomes.

Competitive Landscape

The major global players in the inflammatory myositis treatment market include MEDICAL & BIOLOGICAL LABORATORIES CO., LTD., Cabaletta Bio, Inc., Mallinckrodt plc, AstraZeneca PLC, Pfizer Inc., Novartis AG, Avik Pharmaceutical Ltd., Corbus Pharmaceuticals Holdings, Inc., HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY and LEXICARE PHARMA PVT. LTD. among others. 

Key Developments

• On August 02, 2021, AstraZeneca’s Saphnelo (anifrolumab-fnia) launched in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. Saphnelo is under regulatory review for SLE in the EU and Japan. The Phase III trial in SLE using subcutaneous delivery has been initiated and additional Phase III trials are planned for lupus nephritis, cutaneous lupus erythematosus and myositis.
• On June 15, 2021, the International Myositis Society (iMyoS) is a new society to support the diagnosis and treatment of myositis by implementing interdisciplinary standards of care on a global scale. iMyoS supports the development and harmonization of diagnostic criteria & standards of care for myositis and helps to implement those in all other international & national societies.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global inflammatory myositis treatment market. The pandemic created unprecedented challenges for pharmaceutical industries worldwide, including the global inflammatory myositis treatment market by temporarily disrupting many clinical trials and research activities due to the redirected focus on the COVID-19 pandemic and its related restrictions. The pandemic also disrupted the supply chain of these treatment drugs globally.

Why Purchase the Report?

• To visualize the global inflammatory myositis treatment market segmentation based on disease type, treatment type, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of inflammatory myositis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global inflammatory myositis treatment market report would provide approximately 61 tables, 61 figures, and 187 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Suggestions for Related Report

• Global Immunosuppressants Drugs Market
• Global Anti-Inflammatory Drugs Market
• Global Adrenocortical Hormones API Market

For more Pharmaceutical related reports, please click here